NEWS RELEASE

enGene to Participate in the Piper Sandler 38th Annual Healthcare Conference

2026-11-24

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that Ron Cooper, enGene’s President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026 at 10:30 a.m. ET.

A live webcast of the fireside chat can be accessed on the Events and Presentations page of enGene’s investor website, **investors.engene.com**.

About enGene

enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease.

Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

To learn more, please visit **enGene.com** and follow us on **LinkedIn**, **X** and **BlueSky**.

Media and Investor Contact:

Lauren Hopfer

Lhopfer@engene.com

Source: enGene Therapeutics Inc.